AUS
NZ
UK
CA
USA
IND
Highlights
- Recce Pharmaceuticals Ltd secures complete patent protection for two anti-infective treatments.
- Australian Patent Office grants "Patent Family 3" status to RECCE 327 and RECCE 529.
- Patents provide global protection for manufacturing and administration methods until 2037.
Recce Pharmaceuticals Ltd (ASX:RCE) has achieved a significant milestone by completing the patent process for two of its innovative anti-infective treatments, RECCE 327 (R327) and RECCE 529 (R529). The Australian Patent Office recently granted “Patent Family 3” status, marking a crucial step in safeguarding the company’s intellectual property globally.
The newly granted patent extends protection until 2037, covering the manufacturing process, a unique copolymer created through the same method, and the use of both anti-infectives to combat infections. It also encompasses four methods of administration, including oral, injection, inhalation, and transdermal delivery. This comprehensive coverage ensures these treatments are well-protected in key pharmaceutical markets worldwide.
The patent approval signifies not just national recognition but also the importance of these anti-infectives in addressing life-threatening infections. With the Australian Patent Office’s confirmation, Recce now boasts total patent protection for R327 and R529 across major global markets.
Recce Pharmaceuticals' chief executive officer James Graham expressed enthusiasm for this breakthrough, highlighting the transformative potential of the company’s anti-infective therapies. He emphasized that achieving complete patent protection strengthens their global intellectual property portfolio, allowing Recce to lead the fight against critical viral and bacterial threats effectively.
“The formal recognition of these treatments underscores their groundbreaking potential,” said Graham. “Patent Family 3 solidifies our position as a leader in innovative therapies, ensuring protection for R327 and R529 until 2037. This milestone highlights our commitment to providing meaningful solutions for patients worldwide.”
The achievement is pivotal in Recce’s mission to deliver novel treatments for infections. The company’s dedication to addressing viral threats and life-threatening infections is reflected in its rigorous patenting process, which now secures the exclusive use of its technologies in the global market.
Recce Pharmaceuticals has been trading at 47 cents, underscoring the market’s attention on its developments. This milestone could further establish its position in the pharmaceutical industry, demonstrating a strong foundation for future advancements in innovative healthcare solutions.
This comprehensive patent protection represents a significant step forward in safeguarding innovative treatments and solidifying Recce’s presence in the competitive pharmaceutical landscape. With a secure patent portfolio, the company is well-positioned to continue its impactful work in developing anti-infective therapies.
